Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade